Ever since the development of the first vaccine more than 200 years ago, vaccinations have
greatly decreased the burden of infectious diseases worldwide, famously leading to the …

Vaccine development against SARS-CoV-2 has been fierce due to the devastating COVID-
19 pandemic and has included all potential approaches for providing the global community …

Background The worst Ebola virus disease (EVD) outbreak in history has resulted in more
than 28,000 cases and 11,000 deaths. We present the final results of two phase 1 trials of an …

Background The unprecedented 2014 epidemic of Ebola virus disease (EVD) prompted an
international response to accelerate the availability of a preventive vaccine. A replication …

Ebolavirus disease causes high mortality, and the current outbreak has spread unabated
through West Africa. Human adenovirus type 5 vectors (rAd5) encoding ebolavirus …

Ebola virus disease in humans is highly lethal, with case fatality rates ranging from 25 to
90%. There is no licensed treatment or vaccine against the virus, underscoring the need for …

Adenoviral vectors are a safe and potently immunogenic vaccine delivery platform. Non-
replicating Ad vectors possess several attributes which make them attractive vaccines for …

Ebola virus (EBOV) entry requires the surface glycoprotein (GP) to initiate attachment and
fusion of viral and host membranes. Here we report the crystal structure of EBOV GP in its …

The latest Ebola virus (EBOV) epidemic spread rapidly through Guinea, Sierra Leone, and
Liberia, creating a global public health crisis and accelerating the assessment of …

Summary Background The 2014 west African Zaire Ebola virus epidemic prompted
worldwide partners to accelerate clinical development of replication-defective chimpanzee …